The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21+
SponsorPrince of Wales Hospital, Shatin, Hong Kong

About this trial

A significant number of patients with severe mitral and tricuspid valve disease have been previously treated with either valve repair with annuloplasty rings or valve replacement with bioprosthetic/mechanical valves. Over time, these bioprosthetic valves and rings may fail resulting in recurrence of the valvular disease. The technical aspects of a re-do operation are complex and these patients are often times at high risk for repeat open surgery. The emergence of transcatheter options may provide a safer and less invasive alternative to open surgery. Majority of the data currently exist for Western cohorts with limited longer-term outcomes. Data on this therapy is particularly lacking in the Asia-Pacific region, especially important in the light of known differences in body habitus and size.

Eligibility criteria

Qualifiers

Age ≥ 21

Had at least one documented Mitral valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve/valve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve/valve-in-ring procedure. (Prospective)

Disqualifiers

Active endocarditis

Any other conditions which investigator deems unsuitable for participation.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

15 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Prince of Wales Hospital, Shatin, Hong Kong

Lead sponsor

National Heart Centre Singapore

Collaborator